secwatch.observer — SEC 8-K summary
======================================

Issuer:     Claritev Corp (CTEV)
CIK:        0001793229
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001793229-22-000114
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MultiPlan Q3 revenue down 13% to $250.5M; net income falls 75%; slashes FY2022 guidance
--------------------------------------------------------------------------------

- Q3 revenue $250.5M (down 13.1% YoY); net income $19.7M (down 74.8%); adjusted EBITDA $172.2M (down 21.2%).
- FY2022 revenue guidance cut to $1,075-1,090M from $1,160-1,200M; adjusted EBITDA lowered to $765-780M from $850-875M.
- Drivers: softer patient utilization and unfavorable mix of medical cost savings; COVID impact estimated at $4-6M revenue.
- Free cash flow $88.2M vs $146.6M in Q3 2021, down 40%.
- Q4 2022 outlook: revenue $235-250M, adjusted EBITDA $155-170M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1793229/000179322922000114/0001793229-22-000114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1793229/000179322922000114/mpln-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001793229-22-000114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer